Gepirone

Summary

Gepirone (CHEMBL284092) is an approved small-molecule serotonergic agonist (ATC N06AX19); indicated across 2 conditions including cocaine dependence and depressive disorder.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N06AX19
• Indications: 2 conditions
• Clinical trials: 1
• Chemistry: 359.5 Da · C19H29N5O2

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL284092
Name	Gepirone
Type	Small molecule
Max phase	4
FDA approved	yes
PubChem CID	55191
ChEBI	CHEBI:135990
ATC	N06AX19
Molecular formula	C19H29N5O2
Molecular weight	359.5
InChIKey	QOIGKGMMAGJZNZ-UHFFFAOYSA-N

SMILES: CC1(CC(=O)N(C(=O)C1)CCCCN2CCN(CC2)C3=NC=CC=N3)C

IUPAC name: 4,4-dimethyl-1-[4-(4-pyrimidin-2-ylpiperazin-1-yl)butyl]piperidine-2,6-dione

ChEBI definition: A member of the class of piperidones that is piperidine-2,6-dione substituted by a 4-[4-(pyrimidin-2-yl)piperazin-1-yl]butyl group at position 1 and two methyl groups at position 4.

Pharmacological roles (ChEBI): serotonergic agonist, antidepressant, anxiolytic drug.

Also known as: Ariza, BMY-13805, Gepirona, Gepirone, Mj-13805, ORG-13011, ORG-33062 FREE BASE, Variza, gepiron ER, GEPIRONE

Parent form; salt/anhydrous children: CHEMBL1204187

Patent coverage: 1,863 distinct patent families (7,299 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

Broader ChEMBL bioactivity targets: 5 (assay-derived). Sample: Adrenergic receptor alpha-1, 5-hydroxytryptamine receptor 1A, D(2) dopamine receptor, 5-hydroxytryptamine receptor 2A, 5-hydroxytryptamine receptor 1A.

Bioactivity

ChEMBL activities: 11 potent at pChembl ≥ 5 of 11 total. Top 30 by potency (10 = 0.1 nM, 6 = 1 µM):

Target	pChembl	Type	Value	Unit	Activity ID
HTR1A	7.89	Ki	13	nM	CHEMBL_ACT_1718551
HTR1A	7.5	Ki	31.8	nM	CHEMBL_ACT_18168817
P19327	7.5	Ki	31.8	nM	CHEMBL_ACT_758624
DRD2	7.24	Ki	58	nM	CHEMBL_ACT_1718562
P19327	7.16	Ki	70	nM	CHEMBL_ACT_154361
HTR1A	7.1	Kd	79.43	nM	CHEMBL_ACT_2930081
HTR1A	6.94	IC50	114	nM	CHEMBL_ACT_617576
HTR1A	6.54	EC50	288	nM	CHEMBL_ACT_1718573
P15823	5.62	Ki	2400	nM	CHEMBL_ACT_1718556
HTR2A	5.44	Ki	3630	nM	CHEMBL_ACT_18168815
DRD2	5.37	Ki	4320	nM	CHEMBL_ACT_18168819

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).

Indication	Trial phase	MONDO	EFO
cocaine dependence	2	MONDO:0005186	EFO:0002610
depressive disorder	2	MONDO:0002050	MONDO:0002009

Clinical trials

Total trials: 1.

Phase distribution

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00000189	PHASE2	COMPLETED	Gepirone vs Placebo in Treatment of Cocaine Dependence - 3

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No CPIC/DPWG dosing guideline or drug-level clinical/variant annotations in PharmGKB for this molecule.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).